SCHEMBL683640

SCHEMBL683640

Cc1cccc(C)c1N1CCN(Cn2c(=O)c3c(ncn3C)n(C)c2=O)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.51
MAPK1 P28482 1/20 0.49
ADORA2B P29275 8/20 0.49
GLA P06280 1/20 0.48
BLM P54132 1/20 0.48
KMT2A Q03164 1/20 0.46
TNF P01375 2/20 0.46
ACHE P22303 2/20 0.45
PIK3CD O00329 1/20 0.45
POLB P06746 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
CNR1 P21554 1/20 0.45
ADORA2A P29274 1/20 0.45
ADORA1 P30542 1/20 0.45
NTSR1 P30989 1/20 0.45
MC3R P41968 1/20 0.45
NOTUM Q6P988 1/20 0.45
SIRT3 Q9NTG7 1/20 0.45
GDA Q9Y2T3 1/20 0.45
NR2E1 Q9Y466 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL683696 0.89 HTR2A (0.48) HTR2AMAPK1ADORA2BGLABLM
SCHEMBL684065 0.88 HTR2A (0.52) HTR2AMAPK1ADORA2BGLABLM
SCHEMBL684023 0.84 HTR2A (0.58) HTR2AMAPK1ADORA2BGLABLM
SCHEMBL684026 0.84 MAPK1 (0.49) HTR2AMAPK1ADORA2BGLABLM
SCHEMBL682830 0.83 ADORA2B (0.50) HTR2AADORA2BGLABLMTNF
SCHEMBL683665 0.83 ADORA2B (0.47) HTR2AMAPK1ADORA2BGLABLM
SCHEMBL683652 0.82 MAPK1 (0.55) HTR2AMAPK1GLATNFUSP2
SCHEMBL682828 0.82 ADORA2B (0.46) HTR2AMAPK1ADORA2BGLABLM
SCHEMBL684376 0.82 ADORA2B (0.46) HTR2AMAPK1ADORA2BGLABLM
SCHEMBL684062 0.82 HTR2A (0.52) HTR2AMAPK1ADORA2BGLABLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF HTR2A 1201/4885MAPK1 470/4885ADORA2B 786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.